Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness — Stella

Recruiting

Back to Platelet Transfusion Refractoriness trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Early testing / Safety & dosing

Sponsor

Keymed Biosciences Co.Ltd

Enrollment target

~110 participants

Started

March 2025

Primary completion

November 2027

Age range

18 Years and older

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov